

DAFTAR PUSTAKA

1. Yano Y, Utsumi T, Lusida MI, Hayashi Y. 2015 Advances in Hepatitis B virus Hepatitis B virus infection in Indonesia. *World J Gastroenterol.* 2015;21:10714-10720.
2. World Health Organization. Hepatitis B. Departement of Communicable Diseases Survaillance and Response . 2012:3.
3. WHO(2016). Hepatitis B fact sheet no. 204. <http://www.who.int/news-room/factsheets/detail/hepatitis-b>.Diakses Desember 2016.
4. Kementerian Kesehatan. Situasi dan Analisis Hepatitis. Pusat Data dan Informasi Kementerian Kesehatan RI.2018:1-8.
5. Kementerian Kesehatan. HASIL UTAMA RISKESDAS 2018.Badan Penelitian dan Pengembangan Kesehatan . 2018:34.
6. Hollinger FB LT. Hepatitis B Virus. In: Knipe DM et al., eds. *Fields Virology*, 4th ed. Philadelphia, Lippincott Williams & Wilkins, 2001:2971 - 3036.
7. Prasetyo AA, Ariapramuda R, Kindi EA, Dirgahayu P, Sari Y, Dharmawan R KS. Men having sex with men in Surakarta, Indonesia: demographics, behavioral characteristics and prevalence of blood borne pathogens. *Southeast Asian J Trop Med Public Health.* 2014;45:1032-1047
8. Souza RD, Foster GR. Diagnosis and treatment of chronic hepatitis B. *J R Soc Med.* 2004;97:318-321
9. Fadrian. Terapi Antiviral Pada Sirosis Hati Dekompensata Terkait Infeksi Virus Hepatitis B. *Majalah Kedokteran Andalas.* 2016;39(1):35-41.
10. Papatheodoridis G, Dimou E, Papadimitropoulos V. Nucleoside Analogues for Chronic Hepatitis B: Antiviral Efficacy and Viral Resistance. *American Journal of Gastroenterology.* 2002.
11. Ellis EL, Mann DA. Clinical evidence for the regression of liver fibrosis. *J Hepatol.* 2012;56(5):1171-1180.
12. Jones F, Sembiring J, Zain LH. Akurasi Diagnostik Fibrosis Hati berdasarkan Rasio Red Cell Distribution Width (RDW) dan Jumlah Trombosit Dibanding dengan Fibroscan pada Penderita Hepatitis B Kronik. *Global Medical and Health Communication.* 2015:104-109.
13. Poynard T, Lebray P, Ingiliz P, et al. Prevalence of liver fibrosis and risk factors in a general population using non-invasive biomarkers (FibroTest). *BMC Gastroenterology.* 2010;10:2-13.
14. Xiong M, Li J, Yang S, Zeng F, Ji Y, Liu J, et al. Influence of Gender and Reproductive Factors on Liver Fibrosis in Patients With Chronic Hepatitis B

- Infection. *Clinical and Translational Gastroenterology*.2019;10:1-9.
15. Stahl EC, Haschak MJ, Popovic B, Brown BN. Macrophages in the aging liver and age-related liver disease. *Front Immunol*. 2018;9:1-13.
 16. Du X, Wang J, Shao L, Hu X, Yang C, Shen L, et al. Histological improvement of long-term antiviral therapy in chronic hepatitis B patients with persistently normal alanine aminotransferase levels. *J Viral Hepat*. 2013;20:328-335.
 17. Li X, Jin G, Xu H, Zhang Z, Zhou H, Yan D, et al. Chronic hepatitis B patients with high liver fibrosis levels should receive antiviral treatment. *Experimental and Therapeutic Medicine*. 2017;13:3624-3630.
 18. Calvaruso V, Crax A. Regression of fibrosis after HBV antiviral therapy . Is cirrhosis reversible ?. *Liver International*.2014;23:85-90.
 19. Papachrysos N, Hytioglou P, Papalavrentios L, Sinakos E. Antiviral therapy leads to histological improvement of HBeAg-negative chronic hepatitis B patients. *Annals of Gastroenterology*. 2015:374-378.
 20. Wahyuni RD. Analisis Derajat Fibrosis Hati dengan Fibroscan, Indeks FIB4, KING'S Score, dan APRI Score pada Penyakit Hepatitis Kronis. *Jurnal Kesehatan Tadulako*. 2016;2(2):42-52.
 21. Li Y, Huang YS, Wang ZZ . Systematic review with meta-analysis: the diagnostic accuracy of transient elastography for the staging of liver fibrosis in patients with chronic hepatitis B. *Aliment Pharmacol Ther*. 2016;43:458-469.
 22. Obeagu EI, Obeagu GU, Nwosu DC. Hepatitis B and Hepatitis C viral infection : A Review. *Int J Curr Res Chem Pharm Sci*. 2018;3:9-21.
 23. Sekiba K, Otsuka M, Ohno M, Yamagami M, Kishikawa T, Suzuki T, et al. Hepatitis B virus pathogenesis : Fresh insights into hepatitis B virus RNA. *World J Gastroenterol*. 2018;24:2261-2268.
 24. Yulia D. Virus Hepatitis B Ditinjau dari Aspek Laboratorium. *Jurnal Kesehatan Andalas*. 2019;8:247-254.
 25. Lamontagne RJ, Bagga S, Bouchard MJ. Hepatitis B Virus Molecular Biology and Pathogenesis. *Hepatoma*. 2016;2:163-186.
 26. Karayiannis P. Hepatitis B virus : virology , molecular biology , life cycle and intrahepatic spread. *Hepatol Int*. 2017;11:500-508.
 27. Soemohardjo S, Gunawan S. Hepatitis B Kronik. In: Setiati S, Alwi I, Sudoyo AW, Simadibrata KM, Setiyohadi B, Syam AF, editors. *Buku Ajar Ilmu Penyakit Dalam*. 6th ed. Jakarta: Interna Publishing; 2017:1965.

28. Sanityoso A. Hepatitis Viral Akut. In: Setiati S, Alwi I, Sudoyo AW, Simadibrata KM, Setiyohadi B, Syam AF, editors. Buku Ajar Ilmu Penyakit Dalam. 6th ed. Jakarta: Interna Publishing; 2017:1955.
29. Perhimpunan Peneliti Hati Indonesia (PPHI). Konsensus Nasional Penatalaksanaan Hepatitis B di Indonesia. Jakarta:PPHI;2017
30. Krajdén M, Art GM, Petric M. The laboratory diagnosis of hepatitis B virus. *Can J Infect Dis Med Microbiol.*2005;16:65-72.
31. Easterbrook PJ, Roberts T, Sands A, Peeling R. Diagnosis of viral hepatitis. *Curr Opin HIV AIDS.*2020;12:302-314
32. Group P, Flisiak R, Halota W, Jaroszewicz J, Juszczak J, Malkowski P, et al. Recommendations for the treatment of hepatitis B in 2017. *Clin Exp Hepatol.*2017;35-46.
33. Zoulim F, Durantel D. Antiviral Therapies and Prospects for a Cure of Chronic Hepatitis B. *Cold Spring Harb Perspect Med.*2015;5:1-21.
34. Hosaka T, Suzuki F, Kobayashi M, Seko Y, Kawamura Y, Sezaki H, et al. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. *Hepatology.*2013;58: 98–107.
35. Ward H, Tang L, Poonia B, Kottlilil S. Treatment of hepatitis B virus : an update. *Future Microbiol.*2016;11:1581-1597.
36. Clercq E De, Férrir G, Kaptein S, Neyts J. Antiviral Treatment of Chronic Hepatitis B Virus (HBV) Infections. *Viruses.* 2010:1279-1305.
37. Rijckborst V, Janssen HLA. The Role of Interferon in Hepatitis B Therapy. *Curr Hepatitis Rep.*2010;9:231-238.
38. Lapostolle W, Bowden S, Locarnini S, Zoulim F, Wursthorn K, Petersen J, et al. Persistence of cccDNA during the natural history of Chronic Hepatitis B and decline during adefovir dipivoxil therapy. *Gastroenterology.* 2004;126 :1750-1758.
39. Maklad S, Mahfouz E, Adel E. Efficacy and Safety of Entecavir 0.5 mg in Treating Naive Chronic Hepatitis B Virus Patients in Egypt : Five Years of Real Life Experience. *Gastroenterol Res.* 2018;11:138-144.
40. Choi HN, Song JE, Lee HC, Jo HH, Lee CH KB. Efficacy of prolonged entecavir monotherapy in treatment- naive chronic hepatitis B patients exhibiting a partial virologic response to entecavir. *Clin Mol Hepatol.* 2015;21:24-31.
41. Amarapurkar DN. Telbivudine : A new treatment for chronic hepatitis B.

- World J Gastroenterol. 2007;13:6150-6155.
42. Kumar R, Teo EK, How HC, Wong TY, Ang TL. A practical clinical approach to liver fibrosis. *Singapore Med J*. 2018;59:628-633.
 43. Aydin MM, Akcali KC. Liver fibrosis. *Turk J Gastroenterol* 2018;2:14-21.
 44. Gani RA, Hasan I, Lesmana RA. Naskah Lengkap The 12th Liver Update and The Annual Scientific Meeting of INA ASL/PPHI 2019. 2017:43-50.
 45. Jieanu CF, Ungureanu BS, Sandulescu DL, Tudorascu DR, Ciurea ME, Purcarea VL. Quantification of liver fibrosis in chronic hepatitis B virus infection. *Journal of Medicine and Life*. 2015;8:285-290.
 46. Parikh P, Ryan JD, Tsochatzis EA. Fibrosis assessment in patients with chronic hepatitis B virus (HBV) infection. *Ann Transl Med*. 2017;5:1-14.
 47. Jung KS, Kim SU. Clinical applications of transient elastography. *Clin Mol Hepatol*. 2012;18:163-173.
 48. Sandrin L, Fourquet B, Hasquenoph JM, Yon S, Fournier C, Mal F, et al. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. *Ultrasound Med Biol*. 2013;29:1705-1713.
 49. Mitchell A, Soloudre C, Pagano C, Verhey J. Transient Elastography for Assessment of Liver Fibrosis and Steatosis : An Evidence-Based Analysis. *Ont Health Technol Assess Ser*. 2015;15:1-45.
 50. Wong GL. Update of liver fibrosis and steatosis with transient elastography (Fibroscan). *Gastroenterology report*. 2013;1:19-26.
 51. Fung JY. Clinical Application of Transient Liver Diseases Assessment of Fibrosis. *Hongkong Med Diary*. 2009;14:2009.
 52. Kementerian Kesehatan RI (2009). Kelompok Usia. Departemen Kesehatan RI. www.depkes.go.id. Diakses Desember 2009.
 53. Hou JL, Xu D, Shi G, Wan M, Goodman Z, Tan D, et al. Long-term telbivudine treatment results in resolution of liver inflammation and fibrosis in patients with chronic hepatitis B. *Adv Ther*. 2015;32:727– 741.
 54. Sun Y, Chen S, You H. Regression of liver fibrosis : evidence and challenges. *Chinese Medical Journal*. 2020;133:1696-1702.
 55. Wei W, Wu X, Zhou J, Sun Y, Kong Y, Yang X. Noninvasive Evaluation of Liver Fibrosis Reverse Using Artificial Neural Network Model for Chronic Hepatitis B Patients. *Computational and Mathematical Methods in Medicine*. 2019;2019:1-8.

56. Shipley LC, Axley PD, Singal AK. Liver Fibrosis : A Clinical Update. *EMJ Hepatol.*2019;7:105-117.
57. Chon YE, Park JY, Myoung S, Jung KS, Kim BK. Improvement of Liver Fibrosis after Long-Term Antiviral Therapy Assessed by Fibroscan in Chronic Hepatitis B Patients With Advanced Fibrosis. *Nat Publ Gr.* 2017:1-10.
58. Berumen J, Baglieri J. Liver fibrosis : Pathophysiology and clinical implications. *Wiley Interdiscip Rev Syst Biol Med.* 2020;1:1-17.
59. Nallagangula KS, Nagaraj SK. Liver fibrosis : a compilation on the biomarkers status and their significance during disease progression. *Future Sci OA.* 2018;4
60. Kim JK, Ma DW, Lee KS, Paik YH. Assessment of hepatic fibrosis regression by transient elastography in patients with chronic Hepatitis B treated with oral antiviral agents. *J Korean Med Sci.* 2014;29:570-575.
61. Okada M, Enomoto M, Kawada N, Nguyen MH. Effects of antiviral therapy in patients with chronic hepatitis B and cirrhosis. *Expert Rev Gastroenterol Hepatol.* 2017;11:1095-1104.
62. Yo IK, Kwon OS, Park JW, Lee JJ, Lee JH, Won IS, et al. The factors associated with longitudinal changes in liver stiffness in patients with chronic hepatitis B. *Clin Mol Hepatol.*2015;21:32-40.
63. Chi X, Xiao H, Shi M, Cai G, Xie Y, Jiang J, et al. Histological improvement in chronic hepatitis B patients treated with bicyclol: Real world experience. *BMC Gastroenterol.* 2019;19:1-8.
64. Couteur D, Cogger V, McCuskey R, Cabo R, Smedsrød B, Sorensen KK, et al. Age-related changes in the liver sinusoidal endothelium: A mechanism for dyslipidemia. *Ann NY Acad Sci.*2007;1114: 79-87.
65. Wakabayashi H, Nishiyama Y, Ushiyama T, Maeba T, Maeta H. Evaluation of the effect of age on functioning hepatocyte mass and liver blood flow using liver scintigraphy in preoperative estimations for surgical patients: comparison with CT volumetry. *J Surg Res.*2002;106:246-253.
66. Boyd A, Bottero J, Miaillhes P, Lascoux-Combe C, Rougier H, Serfaty L, et al. Liver fibrosis regression and progression during controlled hepatitis B virus infection among HIV – HBV patients treated with tenofovir disoproxil fumarate in France : a prospective cohort study. *J Int AIDS Soc.* 2017;20:1-12.
67. Ruggieri A, Gagliardi MC, Anticoli S. Sex-Dependent Outcome of Hepatitis B and C Viruses Infections : Synergy of Sex Hormones and Immune Responses ?. *Front Immunol.* 2018;9:1-7.
68. Jung YK, Yim HJ. Reversal of liver cirrhosis : current evidence and

- expectations. *Korean J Intern Med.* 2017;32:213-228.
69. Chang XM, Chang Y, Jia A. Effects of interferon-alpha on expression of hepatic stellate cell and transforming growth factor-beta1 and alpha-smooth muscle actin in rats with hepatic fibrosis. *World J Gastroenterol.*2005;11:2634-2636.
 70. Dienstag JL, Goldin RD, Heathcote EJ. Histological outcome during long-term lamivudine therapy. *Gastroenterology.* 2003;124:105-117.
 71. Scribano L, Vanin V, Gottardo G, Sacchi D, Paolo F. Role of antiviral therapy in patients with chronic hepatitis B or C virus in preventing the development of hepatocellular carcinoma. *Hepatoma Res.* 2016.
 72. Marcellin P, Gane E, Buti M, Afdhal N, Sievert W, Jacobson IM, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. *Lancet.*2013;381:468-475.
 73. Woo ASJ, Kwok R, Ahmed T. Alpha-interferon treatment in hepatitis B. *Ann Transl Med.* 2017;5:7.
 74. Schiff ER, Lee SS, Chao YC, Kew Yoon S, Bessone F, Wu SS, et al. Longterm treatment with entecavir induces reversal of advanced fibrosis or cirrhosis in patients with chronic hepatitis B. *Clin Gastroenterol Hepatol* 2011;9:274-276.
 75. Li XU, Jin Q, Zhang H, Jing XU, Ding Z, Zhou H. Changes in liver stiffness and its associated factors during oral antiviral therapy in Chinese patients with chronic hepatitis B. *Experimental and Therapeutic Medicine.* 2017:1169-1175.
 76. Tenggara IR, Lesmana CRA, Gani RA. Treatment Response Monitoring of Chronic Hepatitis B Patients using Transient Elastography and Aspartate Aminotransferase-to-Platelet Ratio Index (APRI). *Acta Med Indones.* 2017;49:220-226.
 77. Roderburg C, Tacke F, Trautwein C. Antiviral Therapy in Patients with Viral Hepatitis and Hepatocellular Carcinoma : Indications and Prognosis. *Visc Med.* 2016:121-126.
 78. Kong Y, Sun Y, Zhou J, Wu X, Chen Y, Piao H, et al. Early steep decline of liver stiffness predicts histological reversal of fibrosis in chronic hepatitis B patients treated with entecavir. *J Viral Hepat* 2019;26:576–585.
 79. WHO. Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection. 2015 ; (March). http://apps.who.int/iris/bitstream/10665/154590/1/9789241549059_eng.pdf?ua=1&ua=1.

80. Basyigit S, Sapmaz F, Yeniova AO. Antiviral therapy leads to histological improvement in HBeAg-negative chronic hepatitis B patients. *Ann Gastroenterol.* 2015;28:506-507.
81. Chang TT, Liaw YF, Wu SS, Schiff E, Han KH, Lai CL, et al. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. *Hepatology.* 2010;52:886-893.
82. Yu Y, Wan P, Cao Y, Zhang W, Chen J, Tan L, et al: Hepatitis B virus e antigen activates the suppressor of cytokine signaling 2 to repress interferon action. *Sci Rep.*2017;7: 1729.
83. Jia J, Li Y, Wei C, et al. Factors associated with disease progression and viral replication in patients with chronic hepatitis B virus infection. *Experimental and Therapeutic Medicine.* 2019;17:4730-4740.
84. Fateen AA, Shahin RY. Assessment of hepatic fibrosis and necroinflammation among inactive HBsAg carriers in Egypt. *Ann Hepatol.* 2019;11:464-470.

